

Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2026-06400 Filed 4-1-26; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Advisory Board on Radiation and Worker Health; Notice of Charter Renewal

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice of charter renewal.

SUMMARY: The Centers for Disease Control and Prevention (CDC), within the Department of Health and Human Services (HHS), announces the renewal of the charter of the Advisory Board on Radiation and Worker Health (ABRWH).

FOR FURTHER INFORMATION CONTACT: Rashaun Roberts, Ph.D., Designated Federal Officer, Advisory Board on Radiation and Worker Health, Centers for Disease Control and Prevention, Department of Health and Human Services, 1090 Tusculum Avenue, Mailstop C-24, Cincinnati, Ohio 45226. Telephone: (513) 533-6800; Email: ocas@cdc.gov.

SUPPLEMENTARY INFORMATION: CDC is providing notice under 5 U.S.C. 1001-1014 of the renewal of the charter of the Advisory Board on Radiation and Worker Health, Centers for Disease Control and Prevention, Department of Health and Human Services. This charter has been renewed for a two-year period through March 22, 2028.

The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and

Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2026-06403 Filed 4-1-26; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2026-N-3241]

Issuance of Priority Review Voucher; Rare Pediatric Disease Product; KRESLADI (marnetegrane autotemcel)

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that KRESLADI (marnetegrane autotemcel), approved March 26, 2026, manufactured by Rocket Pharmaceuticals, Inc., meets the criteria for a priority review voucher.

FOR FURTHER INFORMATION CONTACT: Myrna Hanna, Center for Biologics Evaluation and Research, Food and Drug Administration, industry.biologics@fda.hhs.gov, 240-402-7911.

SUPPLEMENTARY INFORMATION: FDA is announcing the issuance of a priority review voucher to the sponsor of an approved rare pediatric disease product application. Under section 529 of the FD&C Act (21 U.S.C. 360ff), FDA will award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA has determined that KRESLADI (marnetegrane autotemcel), manufactured by Rocket Pharmaceuticals, Inc., meets the criteria for a priority review voucher. KRESLADI (marnetegrane autotemcel) is indicated for the treatment of pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) due to biallelic variants in *ITGB2* without an

available human leukocyte antigen (HLA)-matched sibling donor for allogeneic hematopoietic stem cell transplant.

For further information about the Rare Pediatric Disease Priority Review Voucher Program and for a link to the full text of section 529 of the FD&C Act, go to <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/rare-pediatric-disease-rpd-designation-and-voucher-programs>. For further information about KRESLADI (marnetegrane autotemcel), go to the Center for Biologics Evaluation and Research's Approved Cellular and Gene Therapy Products website at <https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products>.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2026-06379 Filed 4-1-26; 8:45 am]

BILLING CODE 4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Document Identifier: OS-0937-0213]

Agency Information Collection Request. 30-Day Public Comment Request

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: In compliance with the requirement of the Paperwork Reduction Act of 1995, the Office of the Secretary (OS), Department of Health and Human Services, submitted an Information Collection Request (ICR) to the Office of Management and Budget (OMB) for review and approval. OMB will accept further comments from the public during the review and approval period.

DATES: Comments on the ICR must be received on or before May 4, 2026.

ADDRESSES: Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/PRAMain. Find this information collection by selecting "Currently under Review" and "Select Agency: Department of Health and Human Services".

FOR FURTHER INFORMATION CONTACT: Tara Rice, tara.rice@hhs.gov or (240) 453-8123. When submitting comments or requesting information, please include the document identifier 0937-0213 and project title for reference.

SUPPLEMENTARY INFORMATION: Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

In the **Federal Register** of January 22, 2026, 91 FR 2786, HHS published a 60-day notice requesting public comment on the proposed collection of information. No comments were received. OPA is proceeding with this 30-day comment period regarding three-year OMB approval for its revised collection instruments.

Title of the Collection: Teen Pregnancy Prevention Performance Measures Collection.

Type of Collection: Revision.

OMB No.: 0937–0213.

Abstract: The Office of Population Affairs (OPA), in the Office of the Assistant Secretary for Health (OASH), U.S. Department of Health and Human Services (HHS), requests a revision of clearance for the collection of performance measures from FY2023 Teen Pregnancy Prevention (TPP) Program grantees. OPA supports two types of grants through the TPP program: projects that replicate TPP program models that have been shown to be effective through rigorous evaluation (Tier 1), and research and demonstration projects that develop and test additional models and innovative strategies to prevent teen pregnancy (Tier 2). Collection of performance measures is a requirement of all TPP awards and is in the Notice of Funding Opportunities (NOFOs). The data collection allows OPA to comply with federal accountability and performance requirements, inform stakeholders of grantee progress in meeting TPP program goals, provide OPA with

metrics for monitoring FY2023 TPP grantees, and facilitate individual grantees' continuous quality improvement efforts within their projects. OPA revised the original clearance to update the estimated number of respondents provided in the original clearance to reflect the number of actual grantees awarded: Tier 1 respondents decreased by 12 (from 70 to 58), Tier 2 Hubs respondents decreased by 4 (from 10 to 6) and Tier 2 Rigorous Impact respondents decreased by 1 (from 16 to 15). The decrease in respondents reduced total burden by 222 hours (from 1,431 hours to 1,209 hours). OPA added one new item to the Tier 2 Hubs form (prototypes developed per reporting period). Grantees are already collecting prototypes per period to report another approved item (the total number of prototypes developed to date), and this item should not change the burden estimated for the form. OPA requests clearance for three years.

ANNUALIZED BURDEN HOUR TABLE

Forms (if necessary)	Respondents (if necessary)	Number of respondents	Number of responses per respondent	Average burden per response (hours)	Total burden hours
TPP Tier 1 & Tier 2 Rigorous Impact grantees.	TPP Tier 1 & Tier 2 Rigorous Impact grantees.	73	2	8	1,168
Supportive Services	Tier 1 Grantees	58	2	0.25	29
Tier 2 Innovation Network	Tier 2 Innovation Network Grantees	6	2	1	12
Total					1,209

Catherine Howard,

Paperwork Reduction Act Reports Clearance Officer, Office of the Secretary.

[FR Doc. 2026–06402 Filed 4–1–26; 8:45 am]

BILLING CODE 4150–34–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Document Identifier: OS–4040–0010]

Agency Information Collection Request. 60-Day Public Comment Request

AGENCY: Office of the Secretary, Assistant Secretary for Financial Resources (ASFR), HHS.

ACTION: Notice.

SUMMARY: In compliance with the requirement of the Paperwork Reduction Act of 1995, the Office of the Secretary (OS), Department of Health and Human Services, is publishing the

following summary of a proposed collection for public comment.

DATES: Comments on the ICR must be received on or before June 1, 2026.

ADDRESSES: When commenting, please reference the document identifier/OMB control number OS–4040–0010 and title of collection, “Project/Performance Site Location(s), Project Abstract, and Key Contacts forms”. You may send your comments electronically to sagal.musa@hhs.gov or by calling (202) 578–5441.

FOR FURTHER INFORMATION CONTACT: To obtain copies of supporting material or when submitting comments for the proposed collection(s) summarized in this notice, please include the document identifier 4040–0010–60D and project title for reference, to Sagal Musa, email: sagal.musa@hhs.gov, or call (202) 578–5441.

SUPPLEMENTARY INFORMATION: Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of

information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

Title of the Collection: Project/Performance Site Location(s), Project Abstract, and Key Contacts forms.

Type of Collection: Extension.

OMB No.: 4040–0010.

Abstract: The Project/Performance Site Location(s), Project Abstract, and Key Contacts forms provide the Federal grant-making agencies an alternative to the Standard Form 424 data set and form. Agencies may use Project/Performance Site Location(s), Project Abstract, and Key Contacts forms for grant programs not required to collect